Vetoquinol SA is a France-based veterinary pharmaceutical company specializing in the research, development, production, and marketing of innovative veterinary drugs and non-medicinal care products. Founded in 1933 and headquartered in Lure, it operates as an independent, family-owned business dedicated to enhancing animal health and well-being for companion animals like dogs and cats, as well as livestock including cattle, pigs, sheep, poultry, and horses. Its product portfolio covers key therapeutic areas such as mobility, pain and inflammation management; dermatology, hygiene, and care; anti-parasitics; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology. In 2025, Vetoquinol SA achieved sales revenue of €526 million, with 70% from companion animals and 30% from farm animals, supported by subsidiaries in 24 countries and a network of over 60 distributors reaching approximately 100 countries worldwide. Employing around 2,500 people, the company emphasizes geographical diversification, strategic acquisitions, and close partnerships with veterinarians, farmers, and pet owners to deliver customized solutions. Vetoquinol SA plays a significant role in the global animal health market as one of the top international players, fostering innovation for a better planet.